Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 9/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738732 | 0.91 | PTGS1 (0.48) | PTGS1KMT2APTGS2CYP19A1NR3C2 | |
| SCHEMBL6737475 | 0.91 | PTGS1 (0.62) | PTGS1KMT2APTGS2CYP19A1NR3C2 | |
| SCHEMBL6734355 | 0.87 | PTGS1 (0.64) | PTGS1KMT2APTGS2ALDH1A1CYP19A1 | |
| SCHEMBL6739428 | 0.85 | KMT2A (0.57) | PTGS1KMT2APTGS2ABCB11ALDH1A1 | |
| SCHEMBL6740507 | 0.84 | KMT2A (0.55) | PTGS1KMT2APTGS2ABCB11ALDH1A1 | |
| SCHEMBL6736589 | 0.83 | KMT2A (0.58) | PTGS1KMT2APTGS2ABCB11ALDH1A1 | |
| SCHEMBL6733581 | 0.83 | PTGS1 (0.46) | PTGS1PTGS2CYP19A1NR3C2 | |
| SCHEMBL6739118 | 0.82 | CYP19A1 (0.63) | PTGS1KMT2APTGS2ABCB11ALDH1A1 | |
| SCHEMBL6737927 | 0.81 | PTGS1 (0.57) | PTGS1PTGS2CYP19A1NR3C2 | |
| SCHEMBL6742844 | 0.80 | PTGS1 (0.62) | PTGS1KMT2APTGS2CYP19A1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686390-B2 | DIHYDROFURANONYL- OR DIHYDROPYRROLINONYL-PHENYL COMPOUNDS CONTAINING SUBSTITUTED THIO, SULFOXIDE OR SULFONYL GROUPS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | claimed |
| US-20020032230-A1 | Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. | 2002-03-14 | — | — | US | claimed |
| WO-2001090097-A2 | NOVEL COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-11-29 | — | — | WO | claimed |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6686390-B2 | DIHYDROFURANONYL- OR DIHYDROPYRROLINONYL-PHENYL COMPOUNDS CONTAINING SUBSTITUTED THIO, SULFOXIDE OR SULFONYL GROUPS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-02-03 | — | — | US | disclosed |
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-20020032230-A1 | Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. | 2002-03-14 | — | — | US | disclosed |
| WO-2001090097-A2 | NOVEL COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS1 4/4885KMT2A 1836/4885PTGS2 5/4885 |
| US-20020032230-A1 | Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPSAB1, ACE | PTGS1 42/4885KMT2A 4740/4885PTGS2 190/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS1 4/4885KMT2A 2035/4885PTGS2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.